Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jong-Mu Sun

Showing results (51-60 of 303) with videos related to

Pageof 31
Sort By:
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|March 18, 2016
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control studyJi Hyun Lee, Ho Yun Lee, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2022
Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II StudyHyun Ae Jung, Sehhoon Park, Yoon-La Choi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALKJong-Mu Sun, Yoon-La Choi, Jae-Kyung Won, et al.
Lung Cancer (Amsterdam, Netherlands)|January 28, 2014
Pleural epithelioid hemangioendothelioma harboring CAMTA1 rearrangementSang Yun Ha, In Ho Choi, Joungho Han, et al.
BMC Cancer|October 22, 2025
Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational studyJi Eun Shin, Sehhoon Park, Hyun Ae Jung, et al.
Scientific Reports|October 3, 2019
Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumabYeonghee Eun, In Young Kim, Jong-Mu Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2017
KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung AdenocarcinomaJang Ho Cho, Bo Mi Ku, Jong-Mu Sun, et al.
Plos One|April 12, 2018
Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical modelBo Mi Ku, Moon Ki Choi, Jong-Mu Sun, et al.
Investigational New Drugs|October 25, 2014
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancerBo Mi Ku, Eun Hye Jho, Yeon-Hee Bae, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2014
A new KIT gene mutation in thymic cancer and a promising response to imatinibSung Hee Lim, Ji-Yun Lee, Jong-Mu Sun, et al.
Pageof 31

Showing results (51-60 of 303) with videos related to

Sort By:
Pageof 31
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|March 18, 2016
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control studyJi Hyun Lee, Ho Yun Lee, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2022
Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II StudyHyun Ae Jung, Sehhoon Park, Yoon-La Choi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALKJong-Mu Sun, Yoon-La Choi, Jae-Kyung Won, et al.
Lung Cancer (Amsterdam, Netherlands)|January 28, 2014
Pleural epithelioid hemangioendothelioma harboring CAMTA1 rearrangementSang Yun Ha, In Ho Choi, Joungho Han, et al.
BMC Cancer|October 22, 2025
Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational studyJi Eun Shin, Sehhoon Park, Hyun Ae Jung, et al.
Scientific Reports|October 3, 2019
Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumabYeonghee Eun, In Young Kim, Jong-Mu Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2017
KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung AdenocarcinomaJang Ho Cho, Bo Mi Ku, Jong-Mu Sun, et al.
Plos One|April 12, 2018
Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical modelBo Mi Ku, Moon Ki Choi, Jong-Mu Sun, et al.
Investigational New Drugs|October 25, 2014
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancerBo Mi Ku, Eun Hye Jho, Yeon-Hee Bae, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2014
A new KIT gene mutation in thymic cancer and a promising response to imatinibSung Hee Lim, Ji-Yun Lee, Jong-Mu Sun, et al.
Pageof 31